Aug 26, 2026 7:01 am EDT Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Aug 12, 2026 7:00 am EDT Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Aug 6, 2026 4:01 pm EDT Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Jul 30, 2026 4:01 pm EDT Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 16, 2026 7:00 am EDT Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Jul 14, 2026 7:00 am EDT New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)